The Pharmaceutical Research Shared Resource, consisting of an Investigational Chemotherapy Service and a Cancer Clinical Pharmacology Laboratory, provides a broad range of services to support the conduct of clinical hematology/oncology research. The Investigafional Chemotherapy Service (ICS) is available to all Duke Cancer Institute investigators for the purpose of maintaining drug accountability records and investigafional drug Inventories according to FDA and CTEP guidelines. In addition, this resource provides design consultafion, professional staff educafion, and implementafion services for clinical research studies. The primary focus ofthe Clinical Pharmacology Lab (GPL) is to invesfigate the pharmacokinefics and pharmacodynamics of anticancer drugs and recombinant proteins used in the experimental therapy of cancer. This resource is also available for analysis of endogenous cytokine concentrations during investigational therapy. One of the major goals of the laboratory is to identify predictors of resppnse and toxicity and implement methods to reduce inter-patient variability and drug exposure. The lab provides both consultative and analytic services regarding clinical pharmacokinetic studies of anticancer compounds and recombinant proteins. These include: aid with trial design, opfimal sampling techniques, sample handling and stability, quantitative measurement of drug and metabolite concentrafions (via HPLC, atomic absorpfion spectrophotometry, gas chromatography/mass spectrophotometry, or ELISA), calculation of individual and populafion pharmacokinetic parameters and pharmacometric evaluafion via sophisficated computer modeling programs. This resource has maintained a high level of usage by Duke Cancer Institute investigators including those from the Experimental Therapeutics Program, Breast arid Ovarian Oncology, Hematopoietic Transplantafion and Hematologic Malignancies, Neuro-Oncology, Radiation, and Cancer Biology Programs.

Public Health Relevance

(

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601849
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$85,331
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications